Ospedali Riuniti di Ancona Trials

Ospedali Riuniti di Ancona	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Donati, Abele

ALBIOSS-BAL, NCT03654001 / 2018-001582-16: ALBumin Italian Outcome Septic Shock-BALANCED Trial (ANCED)

Recruiting

1252

Europe

Albumin, Balanced, Ringer Lactate, Ringer Acetate, Crystalsol

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Istituto Di Ricerche Farmacologiche Mario Negri

Septic Shock

12/21

02/22

NCT03954041 / 2018-003858-24: A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

Terminated

Europe, Japan, US, RoW

BIIB093, Glibenclamide, CIRARA, RP 1127, Placebo

Remedy Pharmaceuticals, Inc.

Brain Contusion

06/23

NCT04532138: C-MAC Video Laryngoscope and VS-CMAC Fiberoptic Stylet for Awake Endoscopic Intubation in Predicted Difficult Airways

Recruiting

N/A

Europe

VS-CMAC Rigid Fiberoptic Stylet, C-MAC Video laryngoscope awake intubation, videolaryngoscope with hyperangulated blade

UniversitÃ Politecnica delle Marche

Difficult Airway Intubation

12/20

CPAr, NCT05482945: CardioPulmonary Resuscitation With Argon () Trial

Recruiting

N/A

Europe

Noble gas Argon

Mario Negri Institute for Pharmacological Research

Cardiac Arrest, Out-Of-Hospital, Cardiac Arrest With Successful Resuscitation

03/25

09/25

NCT05403320: Cuff Pressure Control and Evacuation of Subglottic Secretions To Prevent Pneumonia

Completed

N/A

270

Europe, RoW

Continuous cuff pressure regulation, Intermittent cuff pressure regulation, Automatic subglottic secretion drainage, Manual subglottic secretion drainage, Tracheobronchial colonization assessment, Microaspiration assessment, VAP assessment

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart

Respiratory Failure

01/24

04/24

Berardi, Rossana

COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting

758

Europe, Canada, Japan, US, RoW

Cobolimab, Dostarlimab, Docetaxel

GlaxoSmithKline

Lung Cancer, Non-Small Cell

04/25

10/25

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen Inc., Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer

Active, not recruiting

Europe, Canada, Japan, US, RoW

Niraparib, Placebo

GlaxoSmithKline

Neoplasms, Breast

06/24

12/25

KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting

407

Europe, US, RoW

IO102-IO103, Pembrolizumab

IO Biotech, Syneos Health, Merck Sharp & Dohme LLC

Metastatic Melanoma, Unresectable Melanoma

07/25

09/27

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting

600

Europe, Canada, US, RoW

Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere

OncoC4, Inc., BioNTech SE

Non Small Cell Lung Cancer

06/26

06/27

Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting

600

Europe, Canada, Japan, US, RoW

sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel

Seagen Inc.

Carcinoma, Non-Small-Cell Lung

07/26

07/28

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

6000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

DENIM, NCT03610360 / 2017-001774-41: DENdritic Cell Immunotherapy for Mesothelioma

Completed

2/3

176

Europe

MesoPher

Amphera BV, TMC Pharma

Mesothelioma

06/22

PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting

2/3

300

Europe

Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine

Gruppo Oncologico del Nord-Ovest

Biliary Tract Cancer, Cholangiocarcinoma

12/28

01/29

SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Recruiting

112

Europe

CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Neuroendocrine Carcinoma

01/22

BEAT, NCT03896074 / 2018-003973-82: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients

Not yet recruiting

206

Europe

Atezolizumab, Bevacizumab

Fondazione Ricerca Traslazionale

Non-small-cell Lung Cancer Patients

05/22

04/23

HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting

Europe

Abemaciclib, Aromatase Inhibitors

University of Milano Bicocca

Advanced Breast Cancer

12/23

ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting

400

Europe

Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib

Fondazione per la Medicina Personalizzata

Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer

12/24

06/25

CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting

173

Europe

Cetuximab, Erbitux, Avelumab, Bavencio

University of Campania "Luigi Vanvitelli"

Metastatic Colorectal Cancer

07/25

PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting

220

Europe

Giredestrant, Triptorelin, Anastrozole

ETOP IBCSG Partners Foundation, Hoffmann-La Roche

Breast Cancer

06/26

REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

	Data from a trial for NSCLC
	Jan 2022 - Jan 2022: Data from a trial for NSCLC

Active, not recruiting

1/2

284

Europe, Japan, US, RoW

CLN-081, TAS6417; zipalertinib

Cullinan Therapeutics Inc.

Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

12/24

ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting

1/2

359

Europe, Canada, Japan, US, RoW

NVL-520

Nuvalent Inc., Nuvalent, Inc.

Locally Advanced Solid Tumor, Metastatic Solid Tumor

10/25

10/26

ELECTRA, NCT05386108: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting

1/2

Europe, US, RoW

Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio

Stemline Therapeutics, Inc.

Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases

12/25

ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting

1/2

470

Europe, Canada, Japan, US, RoW

NVL-655

Nuvalent Inc., Nuvalent, Inc.

Locally Advanced Solid Tumor, Metastatic Solid Tumor

02/26

03/26

NCT03850067: A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Completed

Europe

CC-90011, Cisplatin, Carboplatin, Etoposide, Nivolumab

Celgene

Small Cell Lung Carcinoma

07/24

NCT04901806: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated

Europe, US, RoW

PBI-200

Pyramid Biosciences

Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor

07/23

ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting

198

Europe, US, RoW

ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1

Enliven Therapeutics

HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

07/26

HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting

N/A

150

Europe

University of Milano Bicocca

Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer

01/24

Imaging-Meso, NCT06581549: Immune Microenvironment and Gene Expression Profiling in Mesothelioma

Recruiting

N/A

220

Europe

Translation analysis

Istituto Oncologico Veneto IRCCS

Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung

12/26

NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting

N/A

1000

Europe

Active systemic or non-systemic treatment (palliative or observation procedure)

Federation of Italian Cooperative Oncology Groups

Carcinoma, Urothelial

11/25

NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting

N/A

300

Europe

Trastuzumab emtansine

Consorzio Oncotech, Roche Pharma AG

Breast Cancer

09/24

05/25

I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting

N/A

300

Europe

Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab

University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza

Non-small Cell Lung Cancer

11/24

RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting

N/A

3000

Europe

Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.

Solid Tumours in Advanced Stages

10/26

NCT04282083: Protocol ITANET - Registry

Recruiting

N/A

3600

Europe

Italian Association Neuroendocrine Tumors

Gastro-entero Pancreatic Neuroendocrine Tumors

07/27

07/32

NCT05550961: APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Recruiting

N/A

1200

Europe

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Politecnico di Milano, Ospedale Policlinico San Martino, Insieme per i Pazienti di Oncologia Polmonare Onlus (IPOP), ASST Grande Ospedale Metropolitano Niguarda, University of Campania "Luigi Vanvitelli", Azienda Ospedaliera dei Colli, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, IRCCS Sacro Cuore Don Calabria di Negrar, Azienda Ospedaliero, Universitaria Ospedali Riuniti, Istituto Clinico Humanitas, Azienda Unità Sanitaria Locale della Romagna, Istituti Ospitalieri di Cremona

NSCLC, Cancer, Lung Cancer, Adenocarcinoma of Lung, Squamous Cell Lung Cancer

10/27

10/32

Carnielli, Virgilio P

NCT04073173: Stress Assessment With and Without Analgesia During Surfactant Therapy in Preterm Infants.

Not yet recruiting

INSURE, LISA, Analgesic, Opioid

Virgilio Paolo Carnielli, Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona, Istituto di Ricerca Pediatrica CittÃ della Speranza

Respiratory Distress Syndrome in Premature Infants

10/22

NCT03693287: Personalized vs Standardized PN for Preterm Infants >1250g

Recruiting

150

Europe

Standardized-parenteral nutrition (S-PN), Personalized-parenteral nutrition (P-PN)

Ospedali Riuniti Ancona, Azienda Ospedaliera di Padova, Hospital Universitario La Paz

Infant,Premature, Parenteral Nutrition, Growth

08/23

10/24

NCT04541095: Growth of Preterm Infants Fed a Infant Milk Formula Containing High Versus Low Amounts of Beta-palmitate

Recruiting

N/A

150

Europe

EX_IMF, ST_IMF

Ospedali Riuniti Ancona, Istituto di Ricerca Pediatrica CittÃ della Speranza, Bunge Loders Croklaan

Weight Gain

12/25

12/27

Ceravolo, Maria Gabriella

TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed

507

Europe, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

Cerevel Therapeutics, LLC

Parkinson Disease

01/24

02/24

RECOVER-19, NCT04456036: Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care

Recruiting

N/A

100

Europe

UniversitÃ Politecnica delle Marche, Maria Gabriella Ceravolo, Michela Coccia, Lauredana Ercolani, Elisa Andrenelli, Lucia Pepa, Rossella Cima, Michela Aringolo

COVID-19

12/20

06/21

RAPIDO, NCT06272448: teleRehabilitation for pAtients With ParkInson's Disease at Any mOment

Completed

N/A

103

Europe

Telerehabilitation

Università Politecnica delle Marche, Universita di Verona

Parkinson Disease

10/24

NCT05363046: Noninterventional Study Evaluating Parkinson's Disease Diary Use

Active, not recruiting

N/A

194

Europe, Canada, US

BlueRock Therapeutics

Parkinson's Disease

10/25

10/26

Marzioni, Marco

VANTAGE, NCT05050136: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting

180

Europe, US, RoW

Volixibat, SHP626, Placebo

Mirum Pharmaceuticals, Inc.

Primary Biliary Cholangitis, PBC

12/25

NCT05618145: National Database on Primary Sclerosing Cholangitis (PSC)

Recruiting

N/A

6000

Europe

Clinical information

University of Milano Bicocca

Primary Sclerosing Cholangitis

10/32

Taccaliti, Augusto

ITCO, NCT04031339: Study of Clinical Outcomes of Thyroid Cancer

Recruiting

N/A

15000

Europe

Standard treatment

University of Roma La Sapienza, Italian Thyroid Cancer Observatory (ITCO) Foundation, Catholic University of the Sacred Heart

Thyroid Neoplasms

01/25

Offidani, Annamaria

NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting

260

Europe, Canada, Japan, US, RoW

LY3454738, Placebo

Eli Lilly and Company

Atopic Dermatitis

06/25

03/26



	Diseases Companies Products Productz Mechanisms of Action Sites